david klow and associates skokie Moshe Klein & David W McDonald, MS, LPC,

Results demonstrated that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo. Critically, the peptide produced no clinically significant alterations in IGF-1 levels, no glucose intolerance or insulin resistance, and no anti-AOD9604 antibodies in any participant

This means that it binds to the same receptors as does endogenous ghrelin (the GHSR-1a receptors) and that it stimulates the cells in the pituitary gland to release more GH without raising ACTH or cortisol levels [3]

This formulation is supplied by Synapse Peptides Australia strictly for laboratory research purposes and is intended for use by qualified researchers in controlled research environments

heart attack)